The CD34+CD38− AML cell subset represents a subset that includes immature and undifferentiated leukemic cells, and a high burden of these cells is associated with chemoresistance and increased relapse risk after potentially curative antileukemic treatment [40]. The gene discussed is CD34; the disease is acute myeloid leukemia.